Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6NXG1
UPID:
ESRP1_HUMAN
Alternative names:
RNA-binding motif protein 35A; RNA-binding protein 35A
Alternative UPACC:
Q6NXG1; A6NHA8; A8MPX1; E9PB47; Q2M2B0; Q499G3; Q6PJ86; Q9NXL8
Background:
Epithelial splicing regulatory protein 1, also known as RNA-binding motif protein 35A or RNA-binding protein 35A, plays a crucial role in mRNA splicing. It specifically regulates the formation of epithelial cell-specific isoforms, including FGFR2-IIIb, and is involved in the splicing of CD44, CTNND1, ENAH, crucial during the epithelial-to-mesenchymal transition. This protein's ability to bind specific sequences in mRNAs, particularly the GU-rich sequence motifs in the ISE/ISS-3 of FGFR2, underscores its significance in gene expression regulation.
Therapeutic significance:
Given its pivotal role in regulating splicing and expression of genes critical for inner ear development and auditory hair cell differentiation, Epithelial splicing regulatory protein 1 is directly linked to Deafness, autosomal recessive, 109. Understanding the role of this protein could open doors to potential therapeutic strategies for sensorineural deafness and vestibular dysplasia, offering hope for targeted interventions in genetic hearing loss conditions.